Health-related quality of life after IMRT or IMRT plus HDR brachytherapy for intermediate or high-risk prostate cancer: Five-year results of a prospective trial.

被引：0
|
作者：
Guix, Benjamin
Maria Lacorte, Teresa
Maria Bartrina, Jose
Ignacio Tello, Jose
Guix, Ines
Galdon, Guillermo
Espino, Marc
Guix, Teresa
机构：
[1] IMOR Fdn, Barcelona, Spain
[2] Imor Fdn, Med Inst Radiotherapy & Oncol, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16071
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Prostate cancer active surveillance and health-related quality of life: results of the Finnish arm of the prospective trial
    Vasarainen, Hanna
    Lokman, Utku
    Ruutu, Mirja
    Taari, Kimmo
    Rannikko, Antti
    BJU INTERNATIONAL, 2012, 109 (11) : 1614 - 1619
  • [22] Deformable Registration and Dose Accumulation for Image-guided HDR Interstitial Brachytherapy (IG-BT) Boost and External Beam Pelvic IMRT (EB-IMRT) for Intermediate and High-risk Prostate Cancer Patients
    Tyagi, N.
    Sebastian, E.
    Liang, J.
    Yan, D.
    Ghilezan, M.
    Martinez, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S731 - S732
  • [23] Moderate Hypofractionation in Intermediate- and High-Risk, Localized Prostate Cancer: Health-Related Quality of Life From the Randomized, Phase 3 HYPRO Trial
    Wortel, Ruud C.
    Oomen-de Hoop, Esther
    Heemsbergen, Wilma D.
    Pos, Floris J.
    Incrocci, Luca
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 103 (04): : 823 - 833
  • [24] Five-Year Outcomes of Proton Therapy in Localized Prostate Cancer on 3 Prospective Trials for Low-, Intermediate-, and High-Risk Prostate Cancer
    Mendenhall, N. P.
    Hoppe, B. S.
    Morris, C. G.
    Nichols, R. C.
    Mendenhall, W. M.
    Su, Z.
    Li, Z.
    Williams, C. R.
    Costa, J.
    Henderson, R. H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S155 - S155
  • [25] Five-year Changes in Health-Related Quality of Life after Biliopancreatic Diversion with Duodenal Switch
    Anny Aasprang
    John Roger Andersen
    Villy Våge
    Ronette L. Kolotkin
    Gerd K. Natvig
    Obesity Surgery, 2013, 23 : 1662 - 1668
  • [26] Five-year Changes in Health-Related Quality of Life after Biliopancreatic Diversion with Duodenal Switch
    Aasprang, Anny
    Andersen, John Roger
    Vage, Villy
    Kolotkin, Ronette L.
    Natvig, Gerd K.
    OBESITY SURGERY, 2013, 23 (10) : 1662 - 1668
  • [27] Health-related quality of life and rates of toxicity after high-dose-rate brachytherapy in combination with external beam radiation therapy for high-risk prostate cancer
    Huang-Tiel, Hui-Juan
    Otto, Isabella
    Golka, Klaus
    Selinski, Silvia
    Koswig, Stephan
    Bathe, Kathrin
    Hallmann, Steffen
    Ecke, Thorsten H.
    INVESTIGATIVE AND CLINICAL UROLOGY, 2020, 61 (03) : 250 - 259
  • [28] A prospective study of health-related quality of life outcomes among men treated for intermediate- and high-risk prostate cancer: the impact of primary and secondary therapies
    Alsinnawi, Mazen
    Cullen, Jennifer
    Hurwitz, Lauren M.
    Levie, Katherine E.
    Burns, John F.
    Rosner, Inger L.
    Brand, Timothy C.
    Stroup, Sean
    Sterbis, Joseph R.
    Rice, Kevin
    Conti, Galen
    Porter, Christopher R.
    CANADIAN JOURNAL OF UROLOGY, 2019, 26 (04) : 9809 - 9820
  • [29] PROSTATE CANCER ACTIVE SURVEILLANCE AND HEALTH-RELATED QUALITY OF LIFE: RESULTS OF THE FINNISH ARM OF THE PROSPECTIVE TRIAL (PRIAS)
    Vasarainen, H.
    Lokman, U.
    Ruutu, M.
    Taari, K.
    Rannikko, A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 314 - 314
  • [30] Dose escalation with high-dose-3D-conformal/IMRT (HD-3D-CRT/IMRT) compared with low-dose 3D-conformal/IMRT plus HDR brachytherapy (LD-3D-CRT/IMRT+ HDR-B) for intermediate- or high-risk prostate cancer: Disease control, survival, and toxicity.
    Guix, Ines
    Bartrina, Jose Maria
    Tello, Jose Ignacio
    Garcia, Ivan
    Quinzanos, Luis
    Lacorte, Teresa Maria
    Guix, Teresa
    Guix, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
12345